The laboratory value is measured once. The patient has been changing for years.

Why this spoke matters

One of the most common errors in evaluating von Willebrand disease is to treat a laboratory result as though it were a permanent characteristic of the patient.

It is not.

A VWF activity of 38 IU/dL during baseline health, 68 IU/dL during pregnancy, and 52 IU/dL several years later may all belong to the same person.

Assuming appropriate sample handling and valid assay performance, none of those values is necessarily wrong.

Each describes the biology of a particular moment.

The challenge is not that VWF changes. The challenge is that clinicians may mistake a changing measurement for a fixed biological trait.

Understanding normal VWF variation is therefore not simply about avoiding laboratory error.

It is about interpreting laboratory data within a living, changing biological system.

Every VWF value answers two questions

Every VWF measurement answers a biological question:

How much VWF is measurable today?

But diagnostic interpretation asks a second question:

Does today’s value represent the patient’s underlying hemostatic state?

Those questions are not always answered by the same number.

A laboratory result records today’s biology.

Diagnosis seeks to understand the patient’s more usual biology while also integrating:

• the bleeding phenotype
• family history
• prior VWF measurements
• the circumstances of sampling
• the relationship between VWF antigen, activity, and FVIII
• specialized or genetic testing when indicated

For diagnosis, measurements obtained during baseline health are often the most informative.

For immediate treatment, surgery, pregnancy, or replacement monitoring, however, the current value may be the clinically relevant one.

The same assay can therefore serve different purposes.

Interpretation begins by knowing which question is being asked.

The moving baseline

Many laboratory measurements vary over time.

VWF is particularly sensitive to physiologic state, age, endothelial activation, and clearance.

Its circulating level reflects the interaction of:

• synthesis and endothelial release
• clearance from plasma
• inherited variation
• ABO blood group
• age
• pregnancy
• acute inflammation or illness
• substantial physical or emotional stress
• assay and preanalytic factors

Some of these influences change VWF within the same person over time.

Others, such as ABO blood group and inherited clearance pathways, help establish the person’s underlying distribution of values.

The most useful way to think about baseline is therefore not as one perfect number.

Baseline is a physiologic range that can shift across the life course.

Or, more simply:

The baseline is not a point. It is a trajectory.

Three kinds of movement

The changing nature of VWF can be understood through three forms of movement:

1. Biology moves
2. The patient moves
3. Interpretation moves

1. Biology varies

Stable determinants also matter

VWF is an acute-phase reactant.

Its concentration may rise during:

• infection
• inflammation
• acute bleeding
• trauma
• surgery
• strenuous exercise
• substantial emotional or physiologic stress
• pregnancy

The magnitude of these effects varies among individuals. Ordinary daily activity or minor emotional fluctuation does not automatically invalidate a result. But significant physiologic stress may transiently elevate VWF and obscure a lower underlying baseline.

Hormonal effects also require nuance.

Pregnancy reliably raises VWF and FVIII in most patients with quantitative VWF deficiency. Other endogenous or exogenous hormonal changes may influence levels, but their effects are generally less uniform and less predictable.

Normal physiology changes measured VWF.

But not all variation is dynamic.

Stable determinants also matter

ABO blood group is one of the strongest inherited determinants of VWF concentration. Group O individuals have lower average VWF levels than individuals with non-O blood groups, in part because of more rapid VWF clearance.

That fact provides biological context.

It does not make a low result clinically irrelevant.

Current international guidance does not require ABO-specific diagnostic thresholds. A low VWF value in a patient with abnormal bleeding should not be dismissed merely because the patient has group O blood.

ABO modifies the level. It does not replace clinical interpretation.

---

2. The patient moves

Patients move through different biological and clinical states.

The child reaches menarche.

The young adult becomes pregnant.

The previously healthy patient develops chronic inflammation.

The older adult develops malignancy, cardiovascular disease, renal dysfunction, or a need for antithrombotic therapy.

A patient may be tested:

• during health
• during active bleeding
• after surgery
• during infection
• during pregnancy
• after VWF replacement
• after desmopressin
• decades after the original diagnosis

Each circumstance changes the meaning of the sample.

The direction of change is not always predictable.

Inflammation may raise VWF antigen and activity. Aortic stenosis or mechanical circulatory support may produce acquired loss of high-molecular-weight multimers despite a normal or increased antigen level. Pregnancy may raise antigen substantially while a qualitative defect remains clinically relevant.

The patient changes even when the inherited diagnosis does not.

---

3. Interpretation moves

This is the movement clinicians most often overlook.

The same numeric value may carry different diagnostic implications depending on:

• bleeding history
• age
• prior measurements
• health state at sampling
• assay methodology
• subtype-specific findings
• local diagnostic terminology

A VWF activity of 45 IU/dL should not be interpreted in a vacuum.

Under the 2021 international guideline, a VWF level below 50 IU/dL in a patient with abnormal bleeding supports a diagnosis of type 1 VWD, while a level below 30 IU/dL supports the diagnosis regardless of bleeding history.¹

At the same time, the label applied to a value between 30 and 50 IU/dL may differ across guidelines, institutions, and historical literature. Some clinicians and publications continue to use the term low VWF, especially when discussing partial quantitative deficiency.

The diagnostic threshold does not eliminate the need for context.

A value of 45 IU/dL may have different implications depending on whether it was obtained:

• in a symptomatic patient during baseline health
• during resolution of an inflammatory illness
• during pregnancy
• after a previously documented value below 30 IU/dL
• with discordant antigen and activity results suggesting qualitative dysfunction
• using an assay with recognized analytic limitations

The number may be the same. Its meaning may not be.

Apparent movement may come from the measurement system

Not every change in VWF reflects biology.

Apparent movement may also arise from:

• sample collection
• transport delay
• temperature exposure
• processing conditions
• laboratory-specific reference ranges
• analytic imprecision
• use of different VWF activity assays
• limitations of older ristocetin cofactor methods
• differences between platelet-dependent activity platforms

Preanalytic problems may produce falsely low or otherwise misleading results. Different activity assays may also yield clinically meaningful differences, particularly in patients with qualitative VWF abnormalities or sequence variants affecting ristocetin-dependent testing.

Serial values are most comparable when:

• samples are collected and processed appropriately
• the patient’s physiologic state is documented
• the same assay or analytically comparable assays are used
• antigen, activity, and FVIII are interpreted relationally rather than independently

Before concluding that the biology has moved, ask whether the measurement system has moved.

Repeat testing is interpretation, not repetition

Repeat testing is sometimes described as merely confirming an abnormal value.

Its deeper purpose is to ask:

Was the first result reproducible and representative?

Repeat testing can help evaluate:

• transient physiologic elevation
• persistent quantitative deficiency
• borderline results near a diagnostic threshold
• discordance between phenotype and laboratory findings
• assay-specific inconsistency
• suspected qualitative VWF dysfunction

But repeat testing is not magical.

Serial values may remain difficult to compare if:

• health states differ
• assay methods change
• preanalytic handling is inconsistent
• years have passed and age-related biology has shifted
• treatment was given before sampling

Statistical variation also matters. An unusually low or high result may move closer to the patient’s usual range when repeated, a phenomenon often described as regression toward the mean.

Repeat testing therefore does not automatically reveal the “true” value.

It provides additional observations from which the clinician can infer a more credible range.

Repeat testing refines interpretation rather than merely repeating measurement.

Aging illustrates the moving baseline

VWF commonly increases with age.

In longitudinal cohorts, many patients initially classified as having type 1 VWD or low VWF later moved into higher laboratory categories, including the normal range.²

et laboratory normalization did not clearly track with disappearance of the historical bleeding phenotype.

That does not prove that higher VWF has no clinical value.

It means that normalization by itself does not establish that the prior phenotype or future bleeding risk has resolved.

The important question is therefore not simply:

Has the number changed?

It is:

What does the new number mean in light of the original diagnosis, lifetime bleeding history, prior challenges, and current clinical setting?

Pregnancy illustrates the same principle

Pregnancy provides a particularly clear example of the moving baseline.

VWF and FVIII usually rise substantially during gestation, especially in quantitative VWF deficiency.

These changes improve hemostatic reserve and are clinically important for delivery planning.

But a normal pregnancy-associated value does not necessarily represent the patient’s nonpregnant baseline.

Nor does it, by itself, negate a previously well-established diagnosis.

In type 2 VWD, antigen may rise while functional abnormalities persist. After delivery, VWF and FVIII fall toward baseline, sometimes rapidly, contributing to continued postpartum bleeding risk.

Pregnancy therefore teaches two different lessons:

• for diagnosis, pregnancy values may not represent baseline biology
• for management, current pregnancy values may be essential

The same result may be unrepresentative diagnostically and highly relevant therapeutically.

When the laboratory and the patient disagree

Discordance between laboratory findings and clinical phenotype should prompt curiosity, not automatic allegiance to either the number or the story.

Examples include:

• persistent bleeding despite apparently normal VWF
• markedly reduced VWF with little observed bleeding
• age-related normalization despite a convincing lifetime phenotype
• low antigen with preserved activity
• disproportionately low activity relative to antigen
• unexpectedly low FVIII
• new bleeding in a patient with previously stable inherited VWD

Possible explanations include:

• biologic variation
• limited exposure to hemostatic challenges
• assay or preanalytic problems
• qualitative VWD
• another inherited bleeding disorder
• medication effect
• an acquired VWF disorder
• an anatomic source of bleeding
• an inaccurate or incomplete original diagnosis

The goal is not to decide whether the laboratory or the patient is “right.”

The goal is to determine why they appear to disagree.

Discordance is not diagnostic failure. It is diagnostic information.

Clinical synthesis

It is an observation obtained at one moment within a changing biological and analytic system.

Interpretation requires attention to:

• the reason for testing
• the patient’s health state
• current and prior VWF values
• the bleeding phenotype
• stable modifiers such as ABO blood group
• age and pregnancy
• preanalytic and assay variability
• the relationship among antigen, activity, and FVIII

For diagnosis, ask whether the value reflects the patient’s usual biology.

For management, ask whether the value reflects the patient’s current hemostatic reserve.

The laboratory value is measured once. The patient has been changing for years.